NDAQ
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing...
Read moreDetails
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into...
Read moreDetails
Alset Inc. Announces Closing of $1.5 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
BETHESDA, MD, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Alset Inc. (NASDAQ: AEI) (the “Company”), a diversified company engaged through its...
Read moreDetails
Nasdaq Surges Over 1%; Cerence Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite surging more than 1% on Friday.
Read moreDetails
Expion360 Inc. Announces Closing of $2.6 Million Registered Direct Offering and Private Placement Priced at the Market Under Nasdaq Rules
REDMOND, Ore., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Expion360 Inc. (Nasdaq: XPON) (the “Company”), an industry leader in lithium-ion battery...
Read moreDetails
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology...
Read moreDetails
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing...
Read moreDetails
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to...
Read moreDetails
Nasdaq to Hold Fourth Quarter and Full Year 2024 Investor Conference Call
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) has scheduled its fourth quarter and full year 2024...
Read moreDetails
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Read moreDetails